BioNTech's Breakaway Venture Takes Shape as Morgan Stanley Trims Price Target

BioNTech plans to close three German sites affecting 1,800 jobs as founders prepare a separate mRNA venture; Morgan Stanley trims target to $114.

Mainz-based BioNTech is navigating a delicate dual transition: dismantling a chunk of its German manufacturing base while its founding scientists prepare to launch a separate mRNA company. The stock traded at EUR 85.10 in pre-market action, down 0.3%, as investors weighed structural uncertainty against an upcoming quarterly update.

At the heart of the corporate reshuffling sits Arife, the planned venture of co-founders U?ur ?ahin and Özlem Türeci. A company spokesperson confirmed to Handelsblatt that the new entity will be headquartered in Mainz and will focus on next-generation mRNA medicines. Talks over the carve-out — covering assets, intellectual property and staff — have proven thorny, with no reliable completion date in sight. Relations between the founders on one side and the management and supervisory boards on the other have cooled noticeably, according to media reports.

Morgan Stanley Keeps Faith, Trims Target

Ahead of third-quarter results, Morgan Stanley's Terence Flynn nudged his price target down from $115 to $114 while reaffirming an "Overweight" rating. Flynn framed the move as a routine model refresh tied to the pending interim report, incorporating sector trends from data provider IQVIA and intra-year developments. For market participants, the adjustment signals that fundamental confidence endures even as near-term expectations are finely calibrated.

The company's market capitalization stands at EUR 21.58 billion, keeping it a heavyweight in the biopharma sector — though it must juggle internal separation alongside operational retrenchment.

Three Sites, 1,800 Jobs on the Line

BioNTech confirmed on September 28 that its Tübingen, Marburg and Idar-Oberstein facilities will close after failing to attract buyers. Roughly 1,800 employees are affected. Tübingen is slated to shut by the end of 2027, Marburg at the start of 2028, and Idar-Oberstein by the end of 2028. The wind-down will absorb considerable management bandwidth, and investors will be watching how effectively the company contains the associated costs without denting its core business.

Patent Fight Adds Legal Overhang

Compounding the operational strain, a US federal judge on September 28 rejected motions from Pfizer, BioNTech and Moderna seeking dismissal of patent suits brought by Bayer CropScience LLC, Monsanto Company and Monsanto Technology LLC. The litigation centers on alleged infringement of intellectual property covering the mRNA technology used in the companies' COVID-19 vaccines.

Chart Line and Quarterly Print Set the Tone

Technically, the picture hinges on the 200-day moving average at EUR 84.65. Holding above that level keeps the setup constructive; a sustained break below it would likely intensify selling pressure before the earnings release. The stock closed yesterday at EUR 85.35.

The decisive catalyst remains the third-quarter report. Resilient revenue and research spending in line with guidance could reinvigorate the bulls — especially with Morgan Stanley maintaining its positive stance despite the modest target cut. A weak top line, by contrast, could invite further valuation downgrades. For now, the risk persists that restructuring charges weigh on the financial trajectory longer than hoped.